Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2020-10-16
2023-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PrEP Affect Regulation Treatment Innovation
NCT04899024
Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of America.
NCT07281378
PrEP Readiness Interventions for Sustained Motivation (PRISM)
NCT06637436
An Intervention to Improve HIV Pre-exposure Prophylaxis Initiation, Adherence and Linkage to Care for Recently Incarcerated Men Who Inject Drugs.
NCT06316089
Prevention and Risk: Treatment With a New Emphasis on Relationships
NCT03396367
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Contingency Management (CM) - Only (Non-Responder)
Non-responders to CM financial inancial incentives for PrEP clinical evaluation and filling a PrEP prescription in Stage 1 that were randomized to assessments only in Stage 2.
Contingency Management (CM)
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
Motivational Interviewing (MI) - Only (Non-Responder)
Non-responders to two MI sessions focusing on stimulant use, sexual risk, and PrEP use in Stage 1 that were randomized to assessments only in Stage 2
Motivational Interviewing (MI)
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
CM+MI
Non-responders CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription in Stage 1 that were randomized to receive two sessions of MI in Stage 2.
Motivational Interviewing (MI)
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
Contingency Management (CM)
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
MI+CM
Non-responders to two MI sessions focusing on stimulant use, sexual risk, and PrEP use in Stage 1 that were randomized to receive CM financial incentives for PrEP clinical evaluation and filling a PrEP prescription in Stage 2.
Motivational Interviewing (MI)
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
Contingency Management (CM)
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
CM-Only (Responder)
Respnders to CM financial incentives for CM will include financial incentives for rEP clinical evaluation and filling a PrEP prescription in Stage 1.
Contingency Management (CM)
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
MI-Only (Responder)
Responders to two MI sessions focusing on stimulant use, sexual risk, and PrEP use will be delivered in Stage 1.
Motivational Interviewing (MI)
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Motivational Interviewing (MI)
Two motivational interviewing sessions focusing on stimulant use, sexual risk, and PrEP uptake will be delivered via Zoom.
Contingency Management (CM)
CM will include financial incentives for PrEP clinical evaluation and filling a PrEP prescription.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sexually active cisgender sexual minority man
* Reports using stimulants in the past three months
* HIV-negative serostatus
* Meets Centers for Disease Control and Prevention (CDC) criteria for PrEP eligibility
Exclusion Criteria
* Unable to provide informed consent
* Severe psychiatric symptoms (e.g., mania, psychosis) that impair capacity to participate
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
City University of New York
OTHER
National Institute on Drug Abuse (NIDA)
NIH
Florida International University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adam Carrico, PhD
Professor and Chair
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam W Carrico, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Miami
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami School of Medicine
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Davis Ewart L, Larson ME, Ghanooni D, Verhagen R, Manuel J, McCollister K, Fardone E, DeVries B, Dilworth S, Blackstock M, Doblecki-Lewis S, Nahum-Shani I, Grov C, Carrico AW. Getting to yes: Pilot sequential multiple assignment randomized trial of motivational enhancement interventions targeting preexposure prophylaxis use in sexual minority men who use stimulants. Health Psychol. 2025 Mar;44(3):310-320. doi: 10.1037/hea0001489.
Davis-Ewart L, Grov C, Verhagen R, Manuel J, Viamonte M, Dilworth S, O'Dell N, Valentin O, Carr S, Cherenack E, Henderson C, Doblecki-Lewis S, Nahum-Shani I, Carrico AW. Motivational Enhancement Interventions to Increase Pre-Exposure Prophylaxis Use in Sexual Minority Men Who Use Stimulants: Protocol for a Pilot Sequential Multiple Assignment Randomized Trial. JMIR Res Protoc. 2023 Oct 13;12:e48459. doi: 10.2196/48459.
Davis-Ewart L, Grov C, Verhagen R, Manuel J, Viamonte M, Dilworth S, Valentin O, Cherenack EM, Carr S, Doblecki-Lewis S, Nahum-Shani I, Carrico AW. Randomized Controlled Trial of Motivational Enhancement Interventions to Increase Pre-Exposure Prophylaxis Use in Sexual Minority Men Who Use Stimulants. Res Sq [Preprint]. 2023 Apr 20:rs.3.rs-2787003. doi: 10.21203/rs.3.rs-2787003/v1.
Davis-Ewart L, Lee JY, Viamonte M, Colon-Burgos J, Harkness A, Kanamori M, Duncan DT, Doblecki-Lewis S, Carrico AW, Grov C. "The familiar taste of poison": a qualitative study of multi-level motivations for stimulant use in sexual minority men living in South Florida. Harm Reduct J. 2023 Apr 26;20(1):58. doi: 10.1186/s12954-023-00787-w.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20180823
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.